itepekimab: Clinical Trials

7 trials of itepekimab, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 completed, 2 terminated. 7 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	7	Completed 5, Terminated 2

Follow itepekimab: new trials by email Literature Review of itepekimab trials Research Report on itepekimab

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis Without Nasal Polyps	Phase 2	Completed	Sanofi	66	2024-12-16	2026-08-25
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis Itepekimab (SAR440340), Placebo - Bronchiectasis	Phase 2	Completed	Sanofi	314	2024-02-20	2026-10-07
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD Itepekimab SAR440340 - Chronic Obstructive Pulmonary Disease	Phase 2	Completed	Sanofi	49	2022-05-19	2026-08-31
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis REGN3500, REGN3500-Matching Placebo - Atopic Dermatitis	Phase 2	Terminated	Regeneron Pharmaceuticals	129	2018-11-13	2022-06-10
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis REGN3500, Dupilumab, REGN3500 + Dupilumab Combo - Atopic Dermatitis	Phase 2	Terminated	Regeneron Pharmaceuticals	206	2018-11-12	2021-11-01
Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care - Chronic Obstructive Pulmonary Disease	Phase 2	Completed	Sanofi	343	2018-07-16	2022-11-22
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination - Asthma	Phase 2	Completed	Sanofi	296	2018-03-12	2022-06-14

Conditions studied

Sponsors

Countries

Results publications

NIH funding